ABSK011 not checked
Abbisko Therapeutics Co, Ltd · ABSK-011 + atilizumab
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.”In the company’s words, NCT07327034 on ClinicalTrials.gov
- Main trialPhase 2
- “This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until…”In the company’s words, NCT07327034 on ClinicalTrials.gov
- Other names
- ABSK-011 + atilizumab
Other drugs for Hepatocellular Carcinoma (HCC)
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up3
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2027 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | |
| Phase 2Enrolling by invitation | 31 Dec 2028 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | |
| Phase 1Not yet recruiting | 7 Nov 2025 | A Mass Balance Study of [14C]ABSK011 | |
| Phase 1Recruiting | 10 Aug 2026 | A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants | |
| Phase 1Recruiting | 31 Dec 2027 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | |
| Phase 1Completed | 30 Sep 2025 | A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026